BridgeBio Pharma (FRA:2CL) ROE % Adjusted to Book Value: 0.00% (As of Mar. 2026)

What is BridgeBio Pharma ROE % Adjusted to Book Value?

BridgeBio Pharma FRA:2CL -0.61% 66 ROE % Adjusted to Book Value is 0.00% as of Mar. 2026. GuruFocus rates FRA:2CL with a GF Score™ of 66/100 and a GF Value™ of €122.43 (Possible Value Trap). The stock has 7 warning signs investors should review.

BridgeBio Pharma's ROE % for the quarter that ended in Mar. 2026 was 0.00%. BridgeBio Pharma's PB Ratio for the quarter that ended in Mar. 2026 was N/A. BridgeBio Pharma's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was N/A.

BridgeBio Pharma ROE % Adjusted to Book Value Related Terms

BridgeBio Pharma ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for BridgeBio Pharma's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BridgeBio Pharma ROE % Adjusted to Book Value Chart

BridgeBio Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

0.00

BridgeBio Pharma Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

FRA:2CL vs EXEL, IONS, SMMT: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, BridgeBio Pharma's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BridgeBio Pharma ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BridgeBio Pharma's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where BridgeBio Pharma's ROE % Adjusted to Book Value falls into.

Save Embed

66GF Score

BridgeBio Pharma Inc FRA:2CL

ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

BridgeBio Pharma ROE % Adjusted to Book Value Calculation

BridgeBio Pharma's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

BridgeBio Pharma's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

Frequently Asked Questions Learn more about ROE % Adjusted to Book Value →

What does a ROE % Adjusted to Book Value of 0.00% mean?

BridgeBio Pharma (FRA:2CL) has a ROE % Adjusted to Book Value of 0.00% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on BridgeBio Pharma and its competitors.

Is BridgeBio Pharma's ROE % Adjusted to Book Value too high?

BridgeBio Pharma's current ROE % Adjusted to Book Value is 0.00%. Overall, BridgeBio Pharma has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does BridgeBio Pharma's ROE % Adjusted to Book Value compare to EXEL and IONS?

BridgeBio Pharma's ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROE % Adjusted to Book Value for a Biotechnology company?

A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROE % Adjusted to Book Value mean?

A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on BridgeBio Pharma and its competitors. BridgeBio Pharma's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is BridgeBio Pharma stock overvalued right now?

Based on GuruFocus' analysis, BridgeBio Pharma (FRA:2CL) is currently considered Possible Value Trap. The stock's GF Value™ is €122.43, compared to a current price of €59.93 — trading 51% below its estimated fair value. The current ROE % Adjusted to Book Value is 0.00%. BridgeBio Pharma's overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROE % Adjusted to Book Value calculated?

ROE % Adjusted to Book Value is calculated from a company's financial statements. For BridgeBio Pharma (FRA:2CL), the current ROE % Adjusted to Book Value is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BridgeBio Pharma (FRA:2CL) Overvalued in 2026?

Based on GuruFocus' analysis, BridgeBio Pharma stock appears to be undervalued. The current stock price of €59.93 is trading 51% below its estimated GF Value™ of €122.43. GuruFocus considers BridgeBio Pharma to be Possible Value Trap.

Key valuation signals for FRA:2CL:

ROE % Adjusted to Book Value: 0.00%
GF Value™: €122.43 vs. price of €59.93 (51% below fair value)
GF Score™: 66/100 with 7 warning signs

No single metric tells the full story. See the FRA:2CL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BridgeBio Pharma Business Description

Industry Healthcare Biotechnology

Comparable Companies EXEL IONS SMMT ASND AXSM MDGL JAZZ BMRN ARWR CYTK VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges BBIO:USA 1BBIO:Italy

Address 3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304

Website https://www.bridgebio.com

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

66GF Score

Get the complete analysis for FRA:2CL

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€59.93

Price

€122.43

GF Value

View FRA:2CL Analysis

See ROE % Adjusted to Book Value data for all stocks →